RENX Stock Overview
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Renalytix Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.26 |
| 52 Week High | UK£1.50 |
| 52 Week Low | UK£0.10 |
| Beta | 1.91 |
| 1 Month Change | -27.14% |
| 3 Month Change | 117.02% |
| 1 Year Change | -70.86% |
| 3 Year Change | -97.68% |
| 5 Year Change | -83.28% |
| Change since IPO | -78.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| RENX | GB Healthcare Services | GB Market | |
|---|---|---|---|
| 7D | -15.0% | -0.06% | 2.2% |
| 1Y | -70.9% | 52.5% | 0.9% |
Return vs Industry: RENX underperformed the UK Healthcare Services industry which returned 64.1% over the past year.
Return vs Market: RENX underperformed the UK Market which returned 0.6% over the past year.
Price Volatility
| RENX volatility | |
|---|---|
| RENX Average Weekly Movement | 68.7% |
| Healthcare Services Industry Average Movement | 8.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: RENX's share price has been volatile over the past 3 months.
Volatility Over Time: RENX's weekly volatility has increased from 37% to 69% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 102 | James McCullough | renalytix.com |
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Renalytix Plc Fundamentals Summary
| RENX fundamental statistics | |
|---|---|
| Market cap | UK£32.53m |
| Earnings (TTM) | -UK£33.44m |
| Revenue (TTM) | UK£1.93m |
16.9x
P/S Ratio-1.0x
P/E RatioIs RENX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RENX income statement (TTM) | |
|---|---|
| Revenue | US$2.41m |
| Cost of Revenue | US$2.26m |
| Gross Profit | US$152.00k |
| Other Expenses | US$42.00m |
| Earnings | -US$41.85m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | 6.31% |
| Net Profit Margin | -1,736.47% |
| Debt/Equity Ratio | -105.2% |
How did RENX perform over the long term?
See historical performance and comparison